Lofano Giuseppe, Kumar Arun, Finco Oretta, Del Giudice Giuseppe, Bertholet Sylvie
Research Center, Novartis Vaccines and Diagnostics S.r.l. (a GSK Company) , Siena , Italy ; Dipartimento di Biologia e Biotecnologie "Charles Darwin", Università degli Studi di Roma "La Sapienza" , Rome , Italy.
Research Center, Novartis Vaccines and Diagnostics S.r.l. (a GSK Company) , Siena , Italy.
Front Immunol. 2015 Jun 30;6:336. doi: 10.3389/fimmu.2015.00336. eCollection 2015.
Vaccination against influenza is the most effective way to protect the population. Current vaccines provide protection by stimulating functional B- and T-cell responses; however, they are poorly immunogenic in particular segments of the population and need to be reformulated almost every year due to the genetic instability of the virus. Next-generation influenza vaccines should be designed to induce cross-reactivity, confer protection against pandemic outbreaks, and promote long-lasting immune responses among individuals at higher risk of infection. Multiple strategies are being developed for the induction of broad functional humoral immunity, including the use of adjuvants, heterologous prime-boost strategies, and epitope-based antigen design. The basic approach is to mimic natural responses to influenza virus infection by promoting cross-reactive neutralizing antibodies that directly prevent the infection. This review provides an overview of the mechanisms underlying humoral responses to influenza vaccination or natural infection, and discusses promising strategies to control influenza virus.
接种流感疫苗是保护人群的最有效方法。目前的疫苗通过刺激功能性B细胞和T细胞反应来提供保护;然而,它们在特定人群中的免疫原性较差,并且由于病毒的基因不稳定性,几乎每年都需要重新配方。下一代流感疫苗的设计应能诱导交叉反应性,提供针对大流行爆发的保护,并在感染风险较高的个体中促进持久的免疫反应。目前正在开发多种策略来诱导广泛的功能性体液免疫,包括使用佐剂、异源初免-加强策略和基于表位的抗原设计。基本方法是通过促进直接预防感染的交叉反应性中和抗体来模拟对流感病毒感染的自然反应。本综述概述了流感疫苗接种或自然感染后体液反应的潜在机制,并讨论了控制流感病毒的有前景的策略。